Genetics in medicine : official journal of the American College of Medical Genetics · 2025
Real-world outcomes of vosoritide in achondroplasia: A systematic review and meta-analysis of multinational clinical evidence.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Albuquerque Anna Luiza Braga, Dacoregio Maria Inez, Rodrigues Cainã Gonçalves, Bertola Débora Romeo, Zattar Ribeiro Paulo Victor
Аннотация
PURPOSE: Achondroplasia is the most common skeletal dysplasia, caused by gain-of-function variants in FGFR3, resulting in constitutive receptor activation and downstream inhibition of endochondral ossification. In 2021, the first targeted therapy, vosoritide, was approved in some countries after a landmark randomized trial. Although findings are promising, evidence is limited to modest-sized cohorts. To address this, we conducted a systematic review and meta-analysis of available vosoritide data.
METHODS: A systematic search of PubMed, Cochrane, and Embase was conducted. Data were extracted according to Cochrane guidelines. Outcomes consistently reported were synthesized using R (v4.5) to generate forest plots.
RESULTS: Ten studies were analyzed, encompassing 696 pediatric patients. Meta-analysis of single means showed that height z-score variation after 12 months of treatment was 0.32 (95% CI 0.25-0.40), annualized growth rate was 1.82 cm/year higher after treatment (95% CI 1.46-2.18), and the ratio between sitting height and height showed -0.0089 decrease (95% CI -0.0157 to -0.0020). Studies reported uniform profiles of adverse events, mostly limited to mild injection-site related issues and no serious complications.
CONCLUSION: This meta-analysis shows that real-world observational data on vosoritide in children with achondroplasia replicate clinical trial findings, with greater gains in linear growth and a similarly favorable safety profile.
METHODS: A systematic search of PubMed, Cochrane, and Embase was conducted. Data were extracted according to Cochrane guidelines. Outcomes consistently reported were synthesized using R (v4.5) to generate forest plots.
RESULTS: Ten studies were analyzed, encompassing 696 pediatric patients. Meta-analysis of single means showed that height z-score variation after 12 months of treatment was 0.32 (95% CI 0.25-0.40), annualized growth rate was 1.82 cm/year higher after treatment (95% CI 1.46-2.18), and the ratio between sitting height and height showed -0.0089 decrease (95% CI -0.0157 to -0.0020). Studies reported uniform profiles of adverse events, mostly limited to mild injection-site related issues and no serious complications.
CONCLUSION: This meta-analysis shows that real-world observational data on vosoritide in children with achondroplasia replicate clinical trial findings, with greater gains in linear growth and a similarly favorable safety profile.